Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level. CyPath® Lung, bioAffinity Technologies’ first product, is being developed for the detection of early-stage lung cancer.
CyPath® uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells. The technology labels cancer’s ability to stimulate its own growth by hijacking cellular processes that exist in every normal cell. Once labeled with CyPath®, cancer cells fluoresce brightly and can be distinguished from non-cancer cells. bioAffinity Technologies also uses other porphyrin molecules to create new treatments that can deliver lethal cytotoxins selectively to cancer.learn more